Wyeth Oral Contraceptive Librel NDA Will Be Filed By June, Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Librel is "about 10 weeks or less from NDA submission," Wyeth Senior VP Camardo says. Wyeth also is investigating Librel, which allows for the elimination of the menstrual cycle while the product is taken, for the treatment for premenstrual dysphoric disorder.
You may also be interested in...
Wyeth Librel NDA Accepted By FDA
Wyeth expects a standard 10-month review for its continuous-use contraceptive; the NDA for the low-dose levonorgestrel/ethinyl estradiol product was submitted May 27
Wyeth Librel NDA Accepted By FDA
Wyeth expects a standard 10-month review for its continuous-use contraceptive; the NDA for the low-dose levonorgestrel/ethinyl estradiol product was submitted May 27
Barr Scraps Seasonale Ad Revisions, Starts On New DTC Campaign
The company attributes a slowdown in growth for the extended-regimen oral contraceptive to the hiatus in direct-to-consumer advertising. The DTC spots were pulled after FDA objected to the original ad and the revised version. New ads will debut in late spring or early summer, CEO Downey says.